Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 7/20 | 0.43 |
| ▸ | MASP2 | O00187 | 3/20 | 0.43 |
| ▸ | KLK1 | P06870 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | FCER2 | P06734 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906002 | 1.00 | KLKB1 (0.43) | KLKB1MASP2KLK1PSMB5F2 | |
| SCHEMBL1906052 | 0.89 | KLKB1 (0.47) | KLKB1MASP2KLK1MMP1FCER2 | |
| SCHEMBL1902345 | 0.89 | KLKB1 (0.47) | KLKB1MASP2KLK1MMP1FCER2 | |
| SCHEMBL1902781 | 0.89 | KLKB1 (0.43) | KLKB1MASP2KLK1MMP1FCER2 | |
| SCHEMBL1904884 | 0.89 | KLKB1 (0.43) | KLKB1MASP2KLK1MMP1FCER2 | |
| SCHEMBL1907929 | 0.88 | KLKB1 (0.49) | KLKB1MASP2KLK1MMP1FCER2 | |
| SCHEMBL1901838 | 0.86 | CTSB (0.48) | KLKB1MASP2KLK1 | |
| SCHEMBL1901841 | 0.86 | CTSB (0.48) | KLKB1MASP2KLK1 | |
| SCHEMBL1903189 | 0.85 | ALDH1A1 (0.49) | KLKB1MASP2KLK1PSMB5MMP1 | |
| SCHEMBL1903197 | 0.85 | ALDH1A1 (0.49) | KLKB1MASP2KLK1PSMB5MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011051671-A1 | AMINOPYRIDINE DERIVATIVES AS KALLIKREIN INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |